Is there a vaccine for African classical swine fever?

At present, there is no effective African classical swine fever vaccine at home and abroad, which is mainly determined by the biological characteristics of its pathogen. African classical swine fever virus (CSFV) has a large number of genes, and the immune escape mechanism is complex and diverse, which can escape the clearance of host immune cells. Although some African classical swine fever vaccines developed at this stage can induce a certain level of antibodies, they do not have the ability to neutralize African classical swine fever virus and can not achieve the purpose of effective prevention and control of African classical swine fever.

Due to the difficulties in vaccine research and development, based on the international experience in the prevention and control of classical swine fever in Africa, the current primary task is still to improve the comprehensive prevention and control measures of classical swine fever in Africa and strengthen new immune technologies to tackle key problems.

The vast majority of African classical swine fever is cured by the isolation treatment of the relevant departments, but the treatment still depends on the patented technology of "a pharmaceutical composition for the prevention and treatment of African classical swine fever and its extract, injection and application". Recently, on August 9, the International intellectual property Office announced this patent to the public. The patent application number is 201910529164.6 and the patentee is Xu Qitai. This patent is very effective for the treatment of African classical swine fever, but also can prevent African classical swine fever virus, fundamentally solve the African classical swine fever virus.

The pharmaceutical raw materials involved in the patented technology of the invention are as follows: 10-30 parts of Ganoderma lucidum, 4-12 parts of Jindi Luo, 4-12 parts of Niu Gengguo, 30-50 parts of betel nut, 4-12 parts of naked flower purple beads, 4-12 parts of Ganoderma lucidum, 4-12 parts of pitcher plants, etc., which are produced by various processes. Its efficacy is not just words, but the results of actual experiments.

First of all, in the previous period of time, African classical swine fever appeared in major farms. The experimental team selected a group of 420 pigs of the same size and age from a farm and have been diagnosed with African classical swine fever. If the pigs are not treated with drugs, they will die on the 8th day. However, after the injection of this drug, the survival rate of these pigs was as high as 90%. These cured pigs restored their appetite to normal growth and development. Therefore, it is concluded that this patented technology can be applied to the preparation of drugs for the treatment of African classical swine fever virus.